Das Lektin der Mistel in der adjuvanten Therapie beim Mammakarzinom

Author(s): Ko, H., Tunggal, L., Gabius, H. -J., Steuer, M., Uhlenbruck, G., Pulverer, G.

Journal/Book: medwelt. 1993; 44: 217-20.

Abstract: Cellular and humoral aspects of the immunomodulating activity of the galactoside-specific lectin from mistletoe (ML-1) were'' investigated in 50 patients suffering from mammary carcinoma. Regular subcutaneous injections to the optimal dose of ML-1 (1ng per kg body weight,-twice a week, for 4 weeks) yielded notable increases in number of certain lymphocyte subsets (pan T-cells, helper T-cells, natural killer (NK)-cells) which are generally believed to be involved in antitumor immunity. Moreover, ML-1 administration resulted in enhanced expression of interleukin (II)-2 receptors on Iymphatic cells and increased serum levels of acute phase reactants as indicators of cellular and humoral activity,- respectively. In vitro, exposition of human Iymphocytes to ML-1 resulted in enhanced expression of receptors for 11-2 (T-cells) and HLADQ (B-cells), which similarly substantiated the capacity of ML-1 to affect immunological parameters within the host defense system.

Keyword(s): Viscum album

Zurück | Weiter

Das Lektin der Mistel in der adjuvanten Therapie beim Mammakarzinom - erste klinische Erfahrungen